Published in Pharmaceuticals (Basel) on January 14, 2016
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 | NCT00948961
Id-KLH Vaccine + T Cells | NCT01426828
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies | NCT00162500
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma | NCT00988312
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. Oncotarget (2016) 0.77
Targeting the TAM Receptors in Leukemia. Cancers (Basel) (2016) 0.75
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med (2015) 3.05
IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 3.04
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother (2008) 2.21
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood (2002) 1.92
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol (2012) 1.85
Graft-versus-myeloma effect in two cases. Lancet (1996) 1.80
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood (2010) 1.79
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res (2013) 1.75
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood (2001) 1.74
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res (2013) 1.60
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood (2011) 1.60
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Bispecific antibodies. Drug Discov Today (2015) 1.44
Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med (2003) 1.44
New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood (2015) 1.33
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood (2004) 1.31
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother (2013) 1.22
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood (2010) 1.20
Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol (2000) 1.19
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood (2003) 1.04
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res (2014) 1.01
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest (1996) 1.00
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res (2012) 0.96
T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol (2000) 0.96
Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol (2005) 0.96
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol (2010) 0.95
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica (2011) 0.94
Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol (2009) 0.92
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol (2015) 0.92
The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity. Oncoimmunology (2013) 0.90
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant (2003) 0.89
Interleukin-6, a new target for therapy in multiple myeloma? Ann Hematol (1993) 0.89
T cells in myeloma. Hematol Oncol (2003) 0.87
The immune microenvironment of myeloma. Cancer Microenviron (2011) 0.86
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med (2015) 0.86
Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy (2015) 0.84
Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J (2015) 0.84
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia (2014) 0.82
Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma. Cancer Sci (2015) 0.80
Activated T cells armed with bispecific antibodies kill tumor targets. Curr Opin Hematol (2015) 0.77
A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells. Leukemia (2004) 0.77